News

Milliardoppkjøp for gründersuksess -Vi har vært imponerte hele veien , sier bioMérieux-topp Celine Roger-Dalbert. Det franske konsernet legger 1,6 milliarder kroner på bordet for gründereventyret SpinChip. Led hele artikkelen i PDF her.

Kjøpes av fransk magnum-investor SpinChip prises til 1,6 milliarder kroner når selskapet kjøpes av bioMérieux. Les hele artikkelen her.

Milliardoppkjøp for gründersuksess: Prisen åttedoblet på to år – Vi har vært imponert hele veien, sier BioMérieux-topp Celine Roger-Dalbert. Det franske konsernet legger 1,6 milliarder kroner på bordet for gründereventyret SpinChip. Les hele artikkelen her.

Oslo, Norway, 13 January 2025 — SpinChip Diagnostics ASA (“SpinChip”), an innovative diagnostics company developing next-generation Point of Care platforms for in vitro diagnostics, announces its agreement to be acquired by bioMérieux, a global leader in in vitro diagnostics. Under the agreement, bioMérieux will acquire 100% ownership of SpinChip for a Total Enterprise Value of…

Oslo, Norway, 19 November 2024 – SpinChip Diagnostics ASA (“SpinChip”) is pleased to announce the completion of its financing round, successfully securing NOK 60 million in the form of a private placement. The financing round was solely directed towards the Company’s shareholders and was significantly oversubscribed. Coherently, the company would like to extend its gratitude…

Oslo, Norway—14 August 2024—SpinChip announced today that the impressive results of its APACE (Advantageous Predictors of Acute Coronary Syndromes Evaluation) study, have been published in the esteemed peer-reviewed journal in cardiovascular medicine, the Journal of the American College of Cardiology (JACC).1 In the article titled “Clinical and Analytical Performance of a Novel Point-of-Care High-Sensitivity Cardiac…

Oslo, Norway, [22] March 2024 — SpinChip Diagnostics ASA (“SpinChip”), a pioneering diagnostics company developing a next-generation point-of-care platform for in vitro diagnostics, today announcedV the completion of its financing round, successfully securing NOK 145 million in the form of a private placement. The financing round was led by bioMérieux, a world leader in the…

Henter inn fransk magnuminvestor: BioMérieux prises til 12 milliarder europå Paris-børsen og har sine røtter i Louis Pasteurs laboratorium. Nå blir selskapet neste største eier i norsk SpinChip. Les artikkelen i PDF her.

Oslo, Norway – 14 March 2024:  SpinChip Diagnostics (“SpinChip” or the “Company”), a pioneering diagnostics company developing a next-generation point-of-care platform for in vitro diagnostics, announces that bioMérieux, a world leader in the field of in vitro diagnostics, has invested NOK 115 million in SpinChip. As a result of this transaction and depending on the…

Oslo, Norway, 8 January 2024 — SpinChip Diagnostics ASA (“SpinChip”), a pioneering diagnostics company developing a next-generation point-of-care platform for in vitro diagnostics, today announced the completion of its financing round, successfully securing NOK 43 million in the form of a convertible loan. ABG Sundal Collier and Carnegie Investment Bank acted as Joint Bookrunners for the financing round, which was…